World's First TAVR vs. SAVR Trial for Intermediate-to-High Risk Aortic Regurgitation Nears Completion!
Time:
2025-08-15
本文转载自【严道医声网】
Clinical Challenge: The Treatment Dilemma for High-Risk Surgical Patients with Aortic Regurgitation
Aortic Regurgitation (AR), a stealthy threat among valvular heart diseases, has long faced limited treatment options. While traditional Surgical Aortic Valve Replacement (SAVR) is effective, a significant population of elderly patients with multiple comorbidities and poor cardiac function are ultimately denied surgery due to high surgical risk or contraindications. This group urgently needs safer solutions.
Groundbreaking TAVR vs. SAVR Head-to-Head Randomized Controlled Trial Launched
In March 2024, a landmark global "head-to-head randomized controlled trial comparing Transcatheter Aortic Valve Replacement (TAVR) with traditional Surgical Aortic Valve Replacement (SAVR)" was initiated. Co-led by Academician Jian'an Wang of the Second Affiliated Hospital, Zhejiang University School of Medicine, and Professor Nianguo Dong of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this study targets severe AR patients at intermediate-to-high surgical risk. It aims to provide a novel alternative offering "minimally invasive surgery-level efficacy" – overcoming the technical limitations of conventional TAVR for pure AR while avoiding the risks of open-heart SAVR. Utilizing innovative transcatheter implantation techniques, it seeks to achieve long-term outcomes comparable to surgery. The trial involves over 10 centers, with all patients scheduled for 1-year clinical and echocardiographic follow-up.
Study Progress and Interim Results:
The trial is progressing smoothly, with patient enrollment nearing completion. Interim analysis indicates that both procedural success rates and safety metrics meet expected standards.
Valves demonstrate excellent function and morphology. No significant regurgitation observed.
Synergistic Evolution of Minimally Invasive and Surgical Therapies
This study transcends a simple TAVR vs. SAVR comparison; it represents an enrichment and evolution of treatment strategies, providing more precise clinical decision-making:
For low-risk patients: SAVR remains the preferred choice for long-term durability.
For intermediate-to-high-risk patients: DOCS VALVE® emerges as a potential optimal solution.
A participating cardiac surgery expert noted: "The clinical value of this study lies in offering aortic regurgitation patients, previously deemed inoperable due to high risk, outcomes comparable to surgery. This is undoubtedly a major breakthrough in medical technology."
The initiation of the DOCS VALVE® trial signifies more than a single technological breakthrough. It underscores China's increasingly pivotal role in shaping global standards for cardiovascular interventional therapy. The "Chinese Ingenuity" embodied by DOCS VALVE® is bringing new hope for a cure to aortic regurgitation patients worldwide.
Animation of DOCS VALVE Implantation
©2023 Wuhan Vickor Medical Technology Co., Ltd.
This site already supports IPV6 access | SEO | Business License